Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a serious condition that can impair blood flow ...

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...

PAH =pulmonary arterial hypertension; PASMC = pulmonary artery smooth muscle cell; RANTES = regulated by T cells, activation upon secretion; TGF-β = transforming growth factor β; Th = T helper ...

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

all of whom had moderate to marked pulmonary hypertension. The average pulmonary-artery pressure for this group was 61 systolic, 33 diastolic. Seven patients had failure of the right ventricle ...

"Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis" has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients helped delay serious outcomes in the ZENITH trial. Among 172 ...